AUTHORS
Zefeng Xu, Ling Pan2, Wenzheng Yu3, Zhihua Zhang4, Xuliang Shen, MD5, Zongjiu Jiao, MD6, Xin Du, MD, PhD7, Xingli Zhao, MD8, Hongmei Ma9, Ming Hou10, Minghui Duan, MD11, Hongling Peng12, Mingzhen Yang, MD, PhD13, Wei WANG, MD14, Tiejun Gong15, Zhenya Hong16, Qingsong Yin, PhD17, Wen Qin, MD18, Xun Lai19, Sujiang Zhang, MD20, Wei Wang, MD21, Sujun Gao, MD22, Chenglin Li23, Xue Lan Zuo24, Ming Jiang, MS25, Li Bao26, Zhen Cai, MD,PhD27, Min Wei28, Min Zhang29, Xinsheng Xie30, Guoyu Hu31, Xiao Jian32, Xiaojing Yan, MD, PhD33, Yi Wang Sr, PhD34, Zhijian Xiao35
AFFILIATIONS
1 MDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
2 West China Hospital, Sichuan University, Sichuan, China
3 Affiliated Hospital of Binzhou Medical University, Binzhou, China
4 Affiliated Hospital of Chengde Medical University, Chengde, China
5 Heping Hospital Affiliated to Changzhi Medical University, Changzhi, China
6 Xingtai People's Hospital, Xingtai, China
7 Guangdong Provincial People's Hospital, Guangzhou, China
8 Tianjin People's Hospital, Tianjin, China
9 Cangzhou People's Hospital, Cangzhou, China
10 Qilu Hospital of Shandong University, Jinan, China
11 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
12 The Second Xiangya Hospital of Central South University, Changsha, China
13 The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
14 The Affiliated Hospital of Qingdao University, Qingdao, China
15 Harbin First Hospital, Harbin, China
16 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
17 Henan Cancer Hospital, Henan, China
18 The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China
19 Yunnan Cancer Hospital, Kunming, China
20 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
21 The Second Affiliated Hospital of Harbin Medical University, Harbin, China
22 The First Hospital of Jilin University, Changchun, China
23 Linyi People's Hospital, Linyi, China
24 Zhongnan Hospital of Wuhan University, Wuhan, China
25 The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
26 Beijing Jishuitan Hospital, Beijing, China
27 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
28 Liuzhou People's Hospital, Liuzhou, China
29 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
30 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
31 Zhuzhou Central Hospital, Zhuzhou, China
32 Zigong First People's Hospital, Zigong, China
33 The First Affiliated Hospital of China Medical University, Shenyang, China
34 Shanxi Provincial People's Hospital, Taiyuan, China
35 MDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
ABSTRACT
Background:
Rovadicitinib (TQ05105) is a first-in-class JAK/ROCK inhibitor approved in China for the treatment of myelofibrosis (MF). The TQ05105-II-01 study is a randomized, double-blind, parallel-controlled phase 2 trial comparing Rovadicitinib versus hydroxyurea (HU) in JAK inhibitor-naïve patients with intermediate-2 to high-risk MF. Primary results (data cutoff of Oct. 2023) were previously reported. Here we present updated efficacy, safety data and subgroup analysis with an extended data cutoff of April 25, 2025.
Methods:
A total of 107 patients were randomized 2:1 to Rovadicitinib (n=72) or HU (n=35). The primary endpoint was the proportion of patients achieving spleen volume reduction ≥35% (SVR35) at week 24. Secondary endpoints included best SVR35 rate, duration of maintained spleen response with SVR35 (DoMSR), TSS50 (≥50% reduction in MPN-SAF TSS) at week 24, best TSS50 rate, duration of TSS50, hemoglobin (HGB) change, and the red blood cell (RBC) transfusion outcomes. Pre-specified subgroup analyses were performed across clinically relevant patient characteristics. Control patients were permitted to cross over to rovadicitinib after week 24.
Results:
Median follow-up time was 26.0 months. Median age was 64.0. Percentage of female and male were 51.4% and 48.6%. SVR35 at week 24 was significantly higher with rovadicitinib versus HU (58.3% vs 22.9%; p=0.0006), as was the best SVR35 rate (66.7% versus 31.4%; p=0.0006). Mean DoMSR was extended from 8.3±0.5 months in the primary analysis to 25.7±4.6 months in the updated analysis for the test group, while the control group had a mean DoMSR of 21.6±8.4 months. Median DoMSR was not reached in rovadicitinib group, versus 19.3 months in the HU group.
TSS50 at week 24 was achieved by 61.1% in rovadicitinib patients versus 45.7% with HU (p=0.1322). Best TSS50 rate improved from 77.8% (primary analysis) to 81.9% (with longer follow-up, vs. 54.3% for HU; p = 0.0025). Mean duration of TSS50 extended from 7.5±0.6 months (primary analysis) to 21.3±4.1 months in the rovadicitinib arm (vs.14.8±5.8 months for HU).
Among control patients who crossed over to rovadicitinib, 78.3% achieved SVR35 and 87.0% achieved a ≥20% spleen volume reduction as best response. 52.2% achieved TSS50.
Mean HGB change from baseline to week 24 was +0.12 g/L with rovadicitinib versus -7.5 g/L with HU (p = 0.0498), with a continued increasing trend at week 48 (+2.5 g/L) and 92 (+6.6 g/L HGB). In subgroups with no transfusion during follow-up, the mean HGB change at week 24 was +3.13 g/L with rovadicitinib versus -6.47 g/L with HU (p = 0.045). Transfusion rate by week 24 was significantly lower with rovadicitinib (11.1% vs 31.4%; p = 0.0099). At week 24, among patients with transfusion at baseline, 53.3% with rovadicitinib group converted to transfusion independence vs. 0% with HU group (p=0.05).
Subgroup analyses demonstrated consistent superiority of rovadicitinib over HU for SVR35 at week 24 and best SVR35 across all pre-specified subgroups, including age, sex, disease type, MF grade, DIPSS risk, prior MF therapy, time from diagnosis to treatment, baseline HGB, baseline platelet count, spleen volume, and MPN-SAF TSS score.
The safety profile remained consistent with the primary analysis, with neither significant increase in event rates, nor new safety signals. The most common grade ≥3 hematological TEAEs were anemia (29.2% [rovadicitinib] vs. 51.4% [HU]), thrombocytopenia (29.2% vs. 17.1%), decreased lymphocyte count (15.3% vs. 11.4%).
Conclusion:
With extended follow-up, rovadicitinib demonstrated deepening and sustained efficacy in spleen response and symptom control, with a longer duration of response compared to the primary analysis. Rovadicitinib significantly reduced RBC transfusion, and showed a favorable trend toward HGB improvement, and transfusion-independence. Subgroup analyses consistently confirmed superiority of rovadicitinib over hydroxyurea across all clinically relevant patient populations. The tolerability profile remained favorable, supporting rovadicitinib as an effective and well-tolerated treatment option for JAK inhibitor-naïve patients with intermediate-2 or high-risk MF.
Disclosure: This post-hoc analysis was supported by Sanofi. All authors declare no financial conflict of interest.
DISCLOSURES
Zefeng Xu: No relevant conflicts of interest to declare.